Anthos Presents New Analysis from P2 AZALEA-TIMI 71 Study
DAIC
NOVEMBER 18, 2024
Ruff, MD, MPH, senior investigator of TIMI Group and director General Cardiology, Cardiovascular Division, Brigham and Women's Hospital. These data suggest that abelacimab may potentially be an attractive option for those patients who could benefit from anticoagulation and antiplatelet therapy.”
Let's personalize your content